Mark Wahlberg wants to take on the longevity-startup crowd with an affordable gym concept

Mark Wahlberg is back in the gym business, but this time he’s not just writing a check. The actor, who once backed a fitness chain that ended up delisted from the New York Stock Exchange, is now building his own concept. The pitch is straightforward: deliver the perks of the longevity craze—cold plunges, blood panels, protein muffins—without the five-figure membership fees that have become standard among wellness startups.

This is a calculated pivot, not a celebrity vanity project. Wahlberg’s previous gym investment ended in public failure, and he’s clearly studied the market’s pain points. The longevity sector has exploded, but it has also positioned itself as a luxury good, accessible only to those who can afford concierge medicine and biohacking retreats. By targeting the gap between high-end longevity clubs and traditional budget gyms, Wahlberg is betting that the average consumer wants the data and recovery tools, not just the prestige.

The timing matters. As remote work reshapes how people structure their days, fitness has become less about a post-work class and more about integrated health management. People are increasingly managing their own biomarkers, tracking sleep, and seeking recovery protocols—but they’re doing it on a budget. A gym that offers a blood panel alongside a squat rack could capture that shift, especially if it keeps pricing accessible.

Still, the hurdles are real. Gym margins are thin, and adding diagnostic services requires partnerships with labs and healthcare providers. The cold plunge trend may be peaking, and the novelty could wear off. Wahlberg’s name will draw initial attention, but the concept will live or die on execution—and on whether the economics work at scale.

For now, this is a signal worth watching. If Wahlberg can deliver longevity services at a price point that undercuts the startup crowd, he might just have found the formula that his earlier investment lacked. The market will be watching to see if this is a comeback or another cautionary tale.